Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2003

Study Completion Date

August 31, 2005

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

ILX651

Trial Locations (10)

34474

US Oncology / Ocala Oncology, Ocala

37203

Sarah Cannon Cancer Center, Nashville

46227

US Oncology / Central Indiana Cancer Centers, Indianapolis

70115

Hematology and Oncology Specialists, New Orleans

75230

US Oncology / Texas Cancer Center, Dallas

75702

US Oncology / Tyler Cancer Center, Tyler

79410

Joe Arrington Cancer Center, Lubbock

80010

Anshutz Cancer Pavillion, Aurora

85712

US Oncology/ Arizona Clinical Research Center, Tucson

90404

Cancer Institute Medical Group, Santa Monica

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00078455 - Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | Biotech Hunter | Biotech Hunter